DIFFUSE LARGE B-CELL LYMPHOMA

This study tests whether adding the drug acalabrutinib to standard chemotherapy can cure more people with untreated diffuse large B-cell lymphoma, an aggressive blood cancer. About 132 adults will take the pill twice daily for up to 14 days, then receive standard chemo and rituxi…

This study tests whether adding targeted drugs based on a patient's genetic profile to standard chemotherapy (Pola-RCHP) works better than standard chemo alone for people with untreated diffuse large B-cell lymphoma. About 152 adults aged 18-75 with an IPI score of 2-5 will parti…

This study tests whether the drug acalabrutinib can help prevent relapse in people with very high-risk large B-cell lymphoma after they have received cell therapy (stem cell transplant or CAR T-cells). About 24 adults aged 18-70 will take acalabrutinib as a maintenance treatment.…

This early-phase study tests a new type of CAR T cell therapy that targets two proteins (CD79b and CD19) on lymphoma cells. It is for people with non-Hodgkin lymphoma that has come back or not responded to standard treatments. The main goals are to check safety and find the right…

This study tests a new drug, selinexor, added to standard chemotherapy (R-CHOP) for people with a specific genetic type of diffuse large B-cell lymphoma (DLBCL) that has a TP53 mutation. The goal is to see if this combination works better than standard treatment alone. About 42 a…

This early-phase study tests a new treatment called SynKIR-310 for adults with B-cell non-Hodgkin lymphoma that has come back or not responded to at least two prior therapies. The treatment uses a patient's own immune cells, modified to recognize and attack cancer cells. The main…

This early-phase study tests whether giving specially engineered immune cells (CAR T-cells) along with a vaccine can safely prevent B-cell lymphoma from coming back after a stem cell transplant. About 15 adults with aggressive or returning lymphoma will receive the treatment. The…

This study tests a new drug called TQB2825 combined with standard immune-chemotherapy for people with diffuse large B-cell lymphoma (DLBCL), either newly diagnosed or whose cancer has returned. About 90 adults aged 18-80 will take part to see if the combination shrinks tumors and…

This study tests whether adding the experimental drug zilovertamab vedotin to standard chemotherapy (R-CHP) helps people with untreated diffuse large B-cell lymphoma live longer without their cancer growing, compared to the current standard treatment (R-CHOP). About 1,046 partici…

This early-stage study tests a new gene therapy called VNX-101 for people with certain blood cancers (like leukemia and lymphoma) that have returned or not improved with standard treatments. The therapy uses a harmless virus to deliver a gene that helps the immune system attack c…

This study compares two treatment schedules for people with a common type of lymphoma (DLBCL) that is low-risk and hasn't spread. Participants will receive either 4 cycles of R-CHOP followed by 4 doses of rituximab, or 6 cycles of R-CHOP followed by 2 doses of rituximab. The goal…

This study is for people with a type of blood cancer called diffuse large B-cell lymphoma that has come back or not responded to treatment. It tests a procedure called DEB-TACE, where tiny beads filled with chemotherapy are injected directly into the blood vessels feeding large t…

This study tests whether giving a targeted radiation drug (131I-Apamistamab) before standard CAR-T cell therapy can safely improve outcomes for people with relapsed or refractory diffuse large B-cell lymphoma. About 30 adults will receive the radiation dose followed by a commerci…

This study looks at a new way to give radiation to people with a type of lymphoma that has come back or not responded to treatment. The goal is to see if giving radiation in two different schedules (once a day vs. twice a day) to the same tumor is safe and possible before startin…

This study tests a treatment called axicabtagene ciloleucel (a CAR T-cell therapy) in 45 adults whose diffuse large B-cell lymphoma has come back after a long period. The goal is to see if this therapy can make the cancer disappear on scans at 3 months. Participants receive one i…

This study tests a chemotherapy regimen (R-CDOP) plus a drug injected into the spinal fluid (intrathecal methotrexate) to prevent central nervous system relapse in people with a high-risk type of aggressive lymphoma. About 83 adults aged 18-75 who have not yet been treated will t…

This study tests whether a special type of radiation given in very small, frequent doses before CAR-T cell therapy can safely and effectively treat people with relapsed or refractory diffuse large B-cell lymphoma. About 20 adults who have not responded to at least two prior treat…

This study looks at how well the drug epcoritamab works for people with advanced types of lymphoma (DLBCL and FL) in everyday medical practice. About 700 adults who are already scheduled to receive this drug will be followed for up to 3 years. The goal is to see how many patients…

This early-phase study tests a radioactive drug (131-I apamistamab) given before CAR T-cell therapy for people with relapsed or hard-to-treat B-cell acute lymphoblastic leukemia or diffuse large B-cell lymphoma. The goal is to find a safe dose and see if the combination is tolera…

This early-phase study tests a new drug, ONM-501, injected directly into tumors, either alone or with another drug (cemiplimab), in people with advanced solid tumors or lymphomas that have not responded to other treatments. The main goals are to find the safest dose and understan…

This study tests whether adding zanubrutinib to standard chemotherapy (R-CHOP) works better for people with newly diagnosed diffuse large B-cell lymphoma that has a protein called p53. About 41 adults aged 18 to 75 will take part. The goal is to see if the combo shrinks tumors mo…

This study tests a combination of five drugs (venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide, called ViPOR) in people whose B-cell lymphoma has returned or not improved after prior treatment. The goal is to see if this drug mix is safe and how well it works. Pa…

This study tests whether adding three targeted antibodies (tafasitamab, retifanlimab, and rituximab) to standard chemotherapy can safely and effectively treat adults with untreated diffuse large B-cell lymphoma. The goal is to improve cancer-killing power while managing side effe…

This study offers ongoing access to the drug ibrutinib for people with certain blood cancers (like chronic lymphocytic leukemia or mantle cell lymphoma) who are already taking it and benefiting. Researchers will track side effects and disease changes over time. About 700 particip…

This early-phase study tests a new drug called AZD0486 in about 227 people with B-cell non-Hodgkin lymphoma, including types like diffuse large B-cell and follicular lymphoma. The drug is a special antibody that helps the immune system attack cancer cells. The main goals are to c…

This study looks at how well a drug called glofitamab works in Chinese adults whose diffuse large B-cell lymphoma has returned or stopped responding to first treatment. Researchers will track 300 patients to see how long they live without the cancer getting worse and how safe the…

This early-phase study is testing an experimental oral drug called LP-168 in about 60 people with certain blood cancers (like CLL, lymphoma, and Waldenstrom macroglobulinemia) that have returned or not responded to prior therapies. The main goals are to find the safest dose and u…

This early-phase study tests a new type of CAR-T cell therapy that is 'armored' with an anti-PD1 feature to help it fight cancer better. It is for adults with diffuse large B-cell lymphoma that has come back or not responded to standard treatments. The main goals are to check saf…

This study is for people with certain types of lymphoma that came back or didn't respond to treatment. After receiving CAR T-cell therapy, participants will get one or two additional drugs (mosunetuzumab and/or polatuzumab vedotin) to see if they help keep the cancer from returni…

This study is for people with certain types of B-cell or Hodgkin lymphoma. Participants first get a stem cell transplant using their own cells, then receive a targeted drug called polatuzumab vedotin every 3 weeks for up to 8 doses. The goal is to see if this approach is safe and…

This study tests a new treatment called MB-CART2019.1, which uses a patient's own immune cells to fight a type of blood cancer called diffuse large B-cell lymphoma. It is for people whose cancer has come back or not responded to treatment and who cannot have a stem cell transplan…

This study tests a combination of two drugs, acalabrutinib and rituximab, in patients aged 80 and older or those 65-79 who are too frail for standard chemotherapy. The goal is to see if this treatment is safe and effective for controlling diffuse large B-cell lymphoma. About 80 p…

This early-phase study tests whether a personalized cell therapy (CAR-T cells) is safe for people with certain types of Non-Hodgkin lymphoma that have come back or not responded to standard treatments. Up to 36 participants will receive their own immune cells that have been genet…

This study tests an experimental drug called BGB-16673 in people with several types of B-cell cancers (like lymphoma and leukemia) that have come back or not responded to other treatments. The drug works by breaking down a protein (BTK) that helps these cancer cells grow. The tri…

This early-phase study tests whether it is safe and possible to collect a patient's own blood stem cells and give them together with CAR-T cell therapy for people with blood cancers that have come back or not responded to treatment. About 20 adults aged 18 to 85 with certain type…

This study is for people with B-cell acute lymphoblastic leukemia or diffuse large B-cell lymphoma whose manufactured cell therapy (tisagenlecleucel) didn't meet commercial release standards. The goal is to check if this slightly off-spec product is still safe and effective. Abou…

This study tests whether the drug emapalumab can prevent severe cytokine release syndrome (CRS), a common and serious side effect of CAR-T cell therapy, in adults with certain types of non-Hodgkin lymphoma that have come back or not responded to treatment. About 28 participants w…

This early-stage study tests a new type of CAR-T cell therapy for people with certain blood cancers (like leukemia and lymphoma) that have come back or not responded to other treatments. The therapy uses a patient's own immune cells, modified to attack cancer cells, and is made w…

This early-phase study tests whether adding a drug called mosunetuzumab after a stem cell transplant is safe and doable for people with aggressive B cell lymphoma that has come back or not responded to prior treatments. Mosunetuzumab is an engineered antibody that helps the body'…

This study tests whether taking itacitinib pills before CAR-T cell therapy can help people with a type of blood cancer called diffuse large B-cell lymphoma. About 27 adults will receive the combination to see if it improves how long they live without their cancer growing. The goa…

This study tests whether a specific type of stem cell transplant can prevent lymphoma from spreading to the brain in high-risk patients. About 36 people with aggressive B-cell lymphoma who are at high risk for brain relapse will receive a chemotherapy regimen (thiotepa and carmus…

This study tests a new drug combination (glofitamab plus chemotherapy) in 100 people with aggressive B-cell lymphoma that has returned or not responded to prior treatments. The main goal is to see if a special steroid plan can reduce a common side effect called cytokine release s…

This early-phase trial tests a new treatment called CLIC-2201 for people with certain blood cancers (like lymphoma or leukemia) that have not responded to standard therapy or have returned. The treatment uses a patient's own immune cells, which are modified in a lab to better rec…

This study tests whether adding the oral drug zanubrutinib to standard chemotherapy (R-CHOP) helps more people with diffuse large B-cell lymphoma (DLBCL) achieve complete remission. It is for patients whose tumors have certain genetic changes (MYD88, CD79B, NOTCH1 mutations or CD…

This early-stage study tests an experimental drug called ABBV-319 in adults with B-cell lymphomas or chronic lymphocytic leukemia that has come back or not responded to treatment. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. About 1…

This study tests a new drug, DZD8586, combined with other treatments for diffuse large B-cell lymphoma (DLBCL), a fast-growing blood cancer. About 150 adults with untreated or relapsed/refractory DLBCL will participate. The goal is to see if the combination shrinks tumors and to …

This study tests whether adding the immunotherapy drug mosunetuzumab to standard chemotherapy is safe and effective for people with a fast-growing type of lymphoma that has a specific genetic change (c-Myc rearrangement). About 30 adults aged 18-75 who have not yet been treated w…

This early-stage trial tests a new drug called IKS03 in people with advanced B-cell non-Hodgkin lymphoma that has not responded to other treatments. IKS03 is an antibody-drug conjugate designed to deliver a toxic payload directly to cancer cells. The study aims to find the safest…

This early-phase study tests a new treatment for adults with B-cell blood cancers (like lymphoma) that have not responded to prior therapies. Participants receive a special type of immune cell (CAR T-cells) along with a targeted drug called pirtobrutinib, which is given before an…

This study tests whether adding the experimental drug SHR-A1912 to standard chemotherapy (R-GEMOX) helps people with diffuse large B-cell lymphoma whose cancer has come back or not responded to prior treatment. About 280 adults aged 18–79 will be randomly assigned to receive eith…

This study tests a new drug called zilovertamab vedotin in children and young adults (up to age 30) whose blood cancers or solid tumors have come back or not responded to treatment. The goal is to see if the drug is safe and can shrink or control the cancer. About 90 participants…

This study tests a new type of CAR-T cell therapy that targets two proteins (CD19 and CD20) on cancer cells, aiming to treat adults with B-cell blood cancers like lymphoma and leukemia that have not responded to other treatments. The therapy uses the patient's own immune cells, w…

This early-phase trial tests a new type of CAR-T cell therapy (Meta10-19) for adults with relapsed or refractory diffuse large B-cell lymphoma, a blood cancer that has not responded to standard treatments. The therapy adds a metabolic boost to help the immune cells work better. T…

This early-phase trial tests a new drug called ZM008, alone and with another drug (toripalimab), in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find a safe dose and check for side effects. About 100 adults with canc…

This study tests a mix of six drugs (ViPOR-P) in people with B-cell lymphoma that came back or didn't respond to prior treatment. The goal is to see if the combination is safe and can shrink tumors. Up to 55 adults will receive up to six 21-day cycles of oral pills and IV infusio…

This study tests two drugs together for people with Richter transformation, a fast-growing lymphoma that can arise from chronic lymphocytic leukemia. The drugs aim to block cancer growth and help the immune system attack the cancer. About 32 adults who have not responded to or ca…

This study tests whether adding the experimental drug zilovertamab vedotin to standard chemotherapy helps people with diffuse large B-cell lymphoma that has come back or not responded to prior treatment. About 290 adults will be randomly assigned to receive either the new combina…

This study looks at whether a new blood test (ctDNA) can guide doctors to safely give less chemotherapy to certain patients with a type of lymphoma called DLBCL. About 40 newly diagnosed patients will have their blood tested during standard treatment. If the test shows no cancer …

This study aims to find differences in blood chemicals and immune cells between people with primary central nervous system lymphoma (a rare brain cancer), those with a similar lymphoma outside the brain, and healthy volunteers. Researchers will collect blood samples and track pat…

This study looks at how the body processes venetoclax when the tablets are crushed and mixed into a liquid for children and young adults with blood cancers like leukemia or lymphoma. About 30 participants who already take venetoclax this way will have their blood levels measured.…

This study looks at whether a natural cell process called trogocytosis can help predict if CAR-T cell therapy will work for people with a type of blood cancer called diffuse large B-cell lymphoma. Researchers will measure trogocytosis levels in blood samples from 85 patients befo…

This study looks at how changes in the MYC gene relate to the immune environment and treatment outcomes in people with diffuse large B-cell lymphoma or high-grade B-cell lymphoma. Researchers will collect data from 200 patients to understand these links better. No new treatments …

This study looks at how chemotherapy affects memory and thinking in people with a type of blood cancer called diffuse large B-cell lymphoma. Researchers will test cognitive function at the start, after the first chemo cycle, and one year later. They also analyze spinal fluid in s…

This study looks at whether a new DNA test on spinal fluid can find signs of lymphoma spreading to the brain before standard tests do. About 50 people with aggressive B-cell lymphoma at high risk for brain relapse will give spinal fluid samples during their first treatment. The g…

This study looks at whether CAR-T cell therapy, a treatment for certain blood cancers, reduces the protection that past vaccines (like measles or tetanus shots) provide. Researchers will test the blood of 45 adults with multiple myeloma or non-Hodgkin lymphoma before and after CA…

This study looks at how the immune system of people with lymphoma responds to flu and COVID vaccines. Researchers will measure antibody levels and immune cells in 200 participants with different types of lymphoma and compare them to healthy individuals. The goal is to understand …

This study follows up to 500 people who received CAR-T cell therapy for blood cancers like leukemia, lymphoma, or multiple myeloma. Researchers will track participants for up to 15 years to see if any new cancers develop. The goal is to understand the long-term safety of this tre…